Press & News

Press & News2019-12-13T20:02:15+00:00

Latest Articles

Browse a selection of of ImaginAb press and news below.

912, 2019

ImaginAb Initiates Phase II Clinical Trial at Penn Medicine

ImaginAb, Inc., a clinical-stage immuno-oncology imaging company, announces it has initiated its Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at Penn Medicine in Philadelphia, PA. Penn Medicine is one of the world’s leading academic medical centers.

910, 2019

ImaginAb to Present at Innovation Showcase 2019 Hosted by The Lundquist Institute

ImaginAb, Inc., a clinical-stage immuno-oncology imaging company, today announces that its Chief Executive Officer, Ian Wilson, will present an update on ImaginAb and progress achieved with the CD8 ImmunoPET minibody at the upcoming Innovation Showcase 2019 on Monday, October 14, 2019, at The Lundquist Institute (formerly LA BioMed),1124 West Carson Street, Torrance, CA.

710, 2019

ImaginAb Announces Publication of Data on First-In-Human Imaging in Patients with Solid Malignancies in The Journal of Nuclear Medicine

ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces publication of its data in leading peer-reviewed medical radiology publication, The Journal of Nuclear Medicine (JNM). The paper entitled "First-in-human imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting[i]" reports the results from a first in-vivo clinical study to assess the safety, tolerability, and efficacy of ImaginAb’s lead product, CD8 tracer, 89Zr-Df-IAB22M2C, in visualizing the immune system.

110, 2019

ImaginAb Announces participation in Innovative Medicines Initiative ‘Immune cells in the spotlight’

ImaginAb, Inc., a clinical-stage immuno-oncology imaging company, is delighted to be part of ‘Immune-Image,’ the Innovative Medicines Initiative Joint Undertaking (IMI2 JU) project, launching today and which includes top academic institutions, companies, and a patient organization. The project has been awarded a €30 million grant for an initial period of five years to support research into novel tracer strategies for clinical imaging of immune cell dynamics.

2709, 2019

Dr. James Allison’s gripping documentary, Breakthrough

ImaginAb celebrates the first screenings of Science Advisory Board member Dr. James Allison’s gripping documentary, Breakthrough, chronicling his discovery of the ground-breaking medicine that would become pivotal in the development of immunotherapy treatments for cancer.

Load More Posts